Title of Invention	BENZOFURAN DERIVATIVES USEFUL FOR TREATMENT OF MICROBIAL INFECTIONS
Abstract	The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds pharmaceutical compositions containing one or more of those compounds anq especially their use as anti-infectives.

Full Text

Novel Benzofuran Derivatives The present invention relates to novel 2,4-diamino-5-(substituted) pyrimidines, to pharmaceutical compositions containing them, to processes for preparing them and their compositions, to intermediates for making them and to their use in the treatment of microbial infections. Certain 2,4-diamino-5-benzylpyrimidines have been demonstrated to be potent inhibitors of dihydrofolate reductase (DHFR), which catalyses the reduction of dihydrofolic acid to tetrahydrofolic acid (THFA). This property has been shown to result frequently in useful pharmaceutical properties particularly in the treatment of bacterial infections. Thus, U.K. Patent Specification No. 875,562 discloses inter alia 2,4-diamino-5-benzylpyrimidines wherein the benzyl moiety is substituted by three C^ alkoxy groups. Trimethoprim, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, is specifically disclosed in U.K. Patent No. 875, 562 and is the most active antibacterial agent amongst the 2,4-diamino-5-benzylpyrimidines known to date. Due to their mode of action, these benzylpyrimidines potentiate the antibacterial activity of the sulphonamides, and Trimethoprim has been used extensively over the last decade in human therapy in combination with various sulphonamides, and in particular with sulphamethoxazole, for the treatment of bacterial infections. European Patent Applications Nos. 81109631.2 and 83104240.3 disclose inter alia also such type of compounds and their use. In WO 02/10157 similar compounds are described. However, the compounds disclosed hereinafter exhibit a much more potent activity against DHFR including mutated enzyme, a superior bioavailability, and a superior antibacterial activity. It has now been found that a group of novel benzofuran derivatives are more potent than, e. g.,Trimethoprim, and are active against Gram positive pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis or Streptococcus pneumoniae) and Gram negative pathogens (Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Moraxella Cattharalis or Proteus vulgaris). Furthermore, and as mentioned above, the compounds of formula I show a much more potent activity against DHFR including mutated enzyme, a superior bioavailability, and a superior antibacterial activity. Therefore, the present invention relates to novel compounds of the general formula I wherein R1 represents the groups whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group R8 represents lower alkyloxy, lower alkylamino, or lower alkyl with 1 to 4 carbon atoms; R9 represents lower alkyl with 1 to 4 carbon atoms; R8 and R9 together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen. R6 represent hydrogen, halogen, nitro, or lower alkyloxy; R7 represents hydrogen; R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring; R4 represents hydrogen; and pharmaceutical^ acceptable salts thereof. The present invention relates to novel compounds of the general formula r wherein R1 represents the groups whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group R8 represents lower alkyloxy,or lower alkyl with 1 to 4 carbon atoms; R9 represents lower alkyl with 1 to 4 carbon atoms; R8 and R9 together form a 5- or 6- memberecl heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen. R6 represent hydrogen, halogen, nitro, or lower alkyloxy; R7 represents hydrogen; R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring; R4 represents hydrogen; and pharmaceutically acceptable salts thereof. In the definitions of the general formula I - if not otherwise stated - the expression lower alkyl means straight and branched alkyl chain groups with one to four carbon atoms, preferably 1 to 2 carbon atoms. Examples of lower alkyl and groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert.-butyl. These lower alkyl groups may be substituted with halogen atoms or hydroxy, thiol or lower alkoxy groups. Examples are trifluoromethyl, chloromethyl, fluoromethyl, hydroxymethyl, thiomethyl, methoxy, ethoxy, propoxy, butoxy, iso-butoxy, sec.-butoxy and tert-butoxy The expressions lower alkylamino and lower alkoxy are compounds consisting of -NH-lower alkyl and -O-lower alkyl wherein the alkyl group is define as above. The expression heterocyclic ring represents saturated and unsaturated, but not aromatic, five- or six-membered rings containing one to two hetero atoms which may be the same or different and are nitrogen or oxygen atoms. Examples are piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, dihydroimidazolyl, dihydropyrazoyl, pyrazolidinyl or dihydroxazolinyl. The expression halogen means fluorine, chlorine, bromine, and iodine but fluorine, chlorine and bromine are preferred. One preferred group of compounds of the present invention are compounds of the general formula II wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I and; R7 represents hydrogen. A further preferred group of compounds of the present invention are compounds of the general formula III wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I and; R7 represents hydrogen. A further preferred group of compounds of the present invention are compounds of the general formula IV wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I and; R7 represents hydrogen. Preferred compounds are compounds of formula I, r, II, III and IV wherein R5 is hydrogen, methyl, carboxylic acid dimethylamide, carboxylic acid methoxymethylamide, pyrrolidin-1-yl-methanone, morphoIin-4-yl-methanone, or carboxylic acid N,N'-dimethyl-hydrazide; R6 represent hydrogen, fluoro, chloro, bromo, methoxy, or nitro; Especially preferred compounds are compounds selected from the group consisting of: 5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; 5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; 5-[2-(1H-indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4- diamine; 5-[6J7-Dimethoxy-2-(2-methyl-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; 5-[2-(6-FluorO"-1H-indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine- 2,4-diamine; {3-[4-(2,4~Diamino-pyrimidin-5-^ indol-2-yl}-morpholin-4-yl-methanone; 344-(2,4-Diamino-pyrimidin-5-ylmethyl)-67-dimethoxy-benzofuran-2-ylmethyl]-1H^ indole-2-carboxyIic acid diethylamide; 5-[6J-Dimethoxy-2-(5-nitro-1H-indol-3-ylmethyl)-benzofuran^-ylmethyl]-pyrim 2,4-diamine; {3-[4-(2,4-Diamino-pyrimidin-5-ylmethyI^ indol-2-yI}-pyrrolidin-1-yl-methanone; 3-[4-(2)4-Diamino-pyrimidin-5-ylmethyI)-6J-dimethoxy-benzofuran-2-ylmethyl]-5- methoxy-1H-indole-2-carboxylic acid dimethylamide; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6J-dimethoxy-benzofuran-2-ylmethyl]-1H- indole-2-carboxylic acid methoxy-methyl-amide; 5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-yImethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-1H-indole-2-carboxylic acid dimethylamide; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-617-dimethoxy-benzofuran-2-ylmethyl]-5- fluoro-1H-indole-2-carboxylic acid dimethylamide; 5-Chloro-3-[4-(2J4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H- indole-2-carboxylic acid N,N'-dimethyl-hydrazide; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5- fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide; The invention also relates to a process for the manufacture of compounds of the general formula I wherein R1 represents the group wherein R7 represents hydrogen R2, R3, R4, R5 and R6have the meaning given in formula I above which process comprises reacting - as depicted in Scheme 1 - a compound of the general formula V (see PCT Publication WO 02/10157), with the MgBr salt VII of the corresponding indoles VI. Scheme 1 Some of the indoles of general formula VI, wherein R5 represents the group and R6, R8 and R9 have the meaning given in formula I above, are synthesised by reacting the indoles VIM with the corresponding amine IX using EDC and HOBT as activating reagents as described in Scheme 2. The indoles VI so obtained are coupled to the compounds V using the same procedure as described above in Scheme 1 to give the compound of general formula I. Scheme 2 Access to an alternative array of substituents can be achieved by proceeding according to Scheme 3 Scheme 3 The intermediates of the general formula XI and XII are novel compounds which serve as intermediates in the synthesis of active compounds of general formula I. The alcohol X (see PCT Publication WO 02/10157) was oxidised to the aldehyde XI with Mn02 and further coupling under acidic conditions (HBr in acetic acid) with the indoles VI resulted in the dimeric compounds of general formula XII. Reduction of compounds XII using trifluoroborane etherate and triethylsilane gave the compound of general formula I as described in Scheme 3 The invention also relates to a process for the manufacture of compounds of the general formula I wherein R1 represents the group and R2, R3, R4, R5 and R6have the meaning given in formula I above, which process comprises reacting - as depicted in Scheme 4 - a compound of the general formula V (see PCT Publication WO 02/10157), with the corresponding indole moiety VI under basic conditions. Scheme 4 Experimental part Abbreviations: ACN: Acetonitrile ATCC: American type culture collection DMF: Dimethyl formamide DMSO; dimethyl sulfoxide EtOH: Ethanol ESI: Electrospray ionisation FC. Flash chromatography HPLC: High performance liquid chromatography MeOH: methanol MS: Mass spectrometry NMR: Nuclear magnetic resonance TBME: tert-Butyl methyl ether TFA: Trifluoroacetic acid THF: Tetrahydrofuran TLC: Thin layer chromatography EDC: N-Ethyl-N'(3-dimethylaminopropyl)carbodiimide hydrochloric acid salt HOBT: 1-Hydroxybenzotrialzole Et3N: Triethylamine eq: Equivalent The preparation of indoles VI which are not described in the following examples are known from the references: Young, J. Chem. Soc. 1958, 3493-3494; Finger et al. J. Amer. Chem. Soc. 1959, 81, 94-97; Dekhane M., Dodd, R. H., Tetrahedron, 1994, 50,21,6299-6306. General procedure A : Amide coupling (Scheme 2) Under nitrogen, at room temperature and in a flask adapted with a mechanical stirrer, indole-carboxylic acid VIII (1 eq) was dissoveld in DMF. To this solution, the corresponding amine IX (1.1 to 5 eq), EDC (1.2 eq) and HOBT (1.2 eq) were added followed by triethylamine (3 eq).The mixture was stirred overnight at room temperature. After the reaction is completed, the mixture was poured slowly to a NaHC03 solution. After extration with dichloromethane the organic layer was washed with 1 N HCI and brine, dried on MgS04 and evaporated under reduced pressure. The compound VI was obtained as a solid and was used without further purification. Example 1: 5-Chloro-1H-indoIe-2-carboxylic acid dimethylamide (633mg, 55%) was obtained by reacting 5-chloro-1H-indole-2-carboxylic acid (1.0g, 5.10mmol) with dimethylamine hydrochloride (500mg, 6.13 mmol), EDC (1.175g, 6.13mmoI) and HOBT (826mg, 6.13mmol). MS ESI m/z: : 223.0 [M+H]+. Example 2: 5-Fluoro-1H-indole-2-carboxylic acid dimethylamide (791 mgt 69%) was obtained by reacting 5-fluoro-1H-indole-2-carboxyIic acid (1.0g, 5.60mmol) with dimethylamine hydrochloride (550mg, 6.72mmol), EDC (1.30g, 6.72mmol) and HOBT (910mg, 6.72mmol). MS ESI m/z:: 207.0 [M+H]+. Example 3: 1H-lndole-2-carboxylic acid N.N'-dimethyl-hydrazide (937mg, 92%) was obtained by reacting 1H-indole-2-carboxylic acid (1.0g, 6.20mmol) with N,N'-dimethyl-hydrazine (980mg, 7.40mmol), EDC (1.43g, 7.40mmol) and HOBT (1.01g, 7.40mmol). MS ESI m/z: : 204.0 [M+H]+. Example 4: 5-Fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide (2.85 g, 76%) was obtained by reacting 5-fluoro-1H-indole-2-carboxylic acid (3.0 g, 16.74mmol) with 0,N-dimethyl-hydroxylamine (2.45 g, 25.11rnmol), EDC (3.85 g, 20.09mmol) and HOBT (2.71 g, 20.09mmol). MS ESI m/z: : 223.0 [M+H]+. Example 5: 5-Chloro-1 H-indole-2-carboxylic acid methoxy-methyl-amide (952mg, 78%) was obtained by reacting 5-chloro-1H-indole-2-carboxylic acid (1.0g, 5.10mmol) with O.N- dimethyl-hydroxylamine (600mg, 6.13mol), EDC (1.17g, 6.13mmol) and HOBT (826mg, 6.13mmol). MS ESI m/z: : 239.0 [M+H]+. General procedure B: Coupling of the indols with compound V (Scheme 4) To a solution of VI (1.1 eq) in dimethylformamide, cesium carbonate (3.0 eq) or potassium carbonate was added portionwise at room temperature under argon. Compound V (1.0 eq) was added and the mixture was stirred for 2 hours at room temperature until completion. The reaction mixture was quenched with a saturated solution of NaHC03 and extracted with dichloromethane. The organic layer was washed with water, saturated solution of NaCI, dried over MgS04 and evaporated under reduced pressure. The compound I was obtained after purification by FC, gradient from CH2CI2 to CH2CI2/methanol (9/1). Example 6: S-^IH-indol-S-ylmethyO-ej-dimethoxy-benzofuran^-ylmethyll-pyrimidine-Z^- diamine (40mg, 23%) was obtained as a brown solid by reacting 5-(2-chloromethyl- ey-dimethoxy-benzofuran^-ylmethyO-pyrimidine^^-diamine (153mg, 0.397mmol) with cesium carbonate (388mg, 1.19mmol) and indole (51 mg, 0.437mmol). MS ESI m/z: : 430.2 [M+H]+; Structure confirmed by 1H NMR 400 MHz in DMSO-d6. Example 7: 5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran"4-ylmethyl]-pyrimidine-2,4-diamine (120mg, 62%) was obtained as a yellow solid by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine (163mg, 0.342mmol) with cesium carbonate (413mg, 1.26mmol) and 7-methoxy-1H-indole (68mg, 0.465mmol). MS ESI m/z: : 460.2 [M+H]+. Example 8: 5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine (30mg, 18%) was obtained as a brown solid by reacting 5-(2- chloromethyl-ej-dimethoxy-benzofuran^-ylmethyO-pyrimidine^^-diamine (140mg, 0.363mmol) with cesium carbonate (355mg, 1.09mmol) and 5-methoxy-1H-indole (59mg, 0.400mmol). MS ESI m/z: : 460.2 [M+H]+. Example 9: 5-[6J-Dimethoxy-2-(2-methyl-1H-indol-3-yImethyl)-ben2ofuran-4-yimethyl]-pyrimidine-2,4-diamine (27mg, 16%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran^-ylmethyO-pyrimidine^^-diamine (151mg, 0.392mmol) with cesium carbonate (383mg, 1.17mmol) and 2-methyl-1H-indole (56mg, 0.431 mmol). MS ESI m/z: : 444.2 [M+H]+. Example 10: S-^^S-Fluoro-IH-indol-S-ylmethyO-ej-dimethoxy-benzofuran^-ylmethyO-pyrimidine-2,4-diamine (31 mg, 13%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyI)-pyrimidine-2,4-diamine (202mg, 0.524mmol) with cesium carbonate (607mg, 1.573mmoI) and 6-fluoro-1H-indole (78mg, 0.577mmol). MS ESI m/z: : 448.2 [M+H]+. General procedure C: Coupling of the indols with compound V (Scheme 1) To a suspension of VI (6.0 eq) in tetrahydrofurane freshly distilled, a 4.2M-solution of ethyl magnesium bromide in diethyl ether (6.0 eq) was added at 0°C under an argon flux. After stirring 1 hour at 0°C, diethyl ether was added to the resulting mixture to give the compound VII as a beige precipitate. After decantation, the excess of solvent was removed and the compound VII was suspended in dichloromethane. To this suspension, the compound V (1.0 eq) was added portionwise at room temperature under argon and the mixture was stirred overnight. The reaction was complete after stirring 16 hours at room temperature. The resulting mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHC03, with a saturated solution of NaCI, dried over MgS04 and evaporated. The compound I was obtained after purification by FC, gradient from CH2CI2 to CH2CI2/methanol (9/1). Example 11: {3-[4-(2l4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-morpholin-4-yl-methanone (42mg, 15%) was obtained by reacting 5-(2-chloromethyl-ej-dimethoxy-benzofuran^-ylmethyO-pyrimidine^^-diamine (197mg, 0.511 mmol) with the salt of 1H-indol-2-yi)-morpholin-4-yl-methanone obtained by reacting a 4.2M-solution of ethyl magnesium bromide in diethyl ether (0.716mL, 3.07mmol) and (1H-indol-2«yl)-morpholin-4-yl-methanone (706mg, 3.07mmol). MSESIm/z: 543.1 [M+H]+. Example 12: 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran"2-ylmethyl]-1H« indoIe-2-carboxylic acid dimethylamide (43mg, 17%) was obtained by reacting 5-(2-chloromethyl"6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine'2)4«diamine (191 mg? 0.496 mmol) with the salt of H-indole-2-carboxylic acid dimethylamide obtained by reacting a 4.2M~solution of ethyl magnesium bromide in diethyl ether (0.695 mL, 2.97 mmol) and 1H-indole-2-carboxylic acid dimethylamide (560 mg, 2.97 mmol). MS ESI M/Z:: 501.2 [M+H]+; Structure confirmed by 1H NMR 400 MHz in DMSO-d6. Example 13: 5-[6,7-Dimethoxy-2-(5-nitro-1H-indol-3"ylmethyl)-benzofuran-4-ylmethyI]-pyrimidine-2,4-diamine (48mg, 26%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine (153 mg, 0.389 mmol) with the salt of 5-nitro-1H-indole obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (0.783 mL, 2.33 mmol) and 5-nitro-1H-indole (379 mg, 2.33 mmol). MS ESI m/z: 475.2 [M+H]+. Genera! procedure D: Coupling of the indols with compound V (Scheme 1) To a suspension of VI (6.0 eq) in tetrahydrofurane freshly distilled, a 4.2M-solution of ethyl magnesium bromide in diethyl ether (6.0 eq) was added at 0°C under an argon flux. After 1 hour at this temperature, diethyl ether was added to the resulting mixture to give the compound VII as a beige precipitate. After decantation, the excess of solvent was removed and the compound VII was suspended in dichloroethane. To this suspension, the compound V (1.0 eq) was added portionwise at room temperature under argon, zinc chloride (1 eq) was added and the reaction mixture was heated at 70 °C until the reaction was complete. The resulting mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHC03, with a saturated solution of NaCI, dried over MgS04 and evaporated. The compound I was obtained after purification by FC, gradient from CH2CI2 to CH2CI2/methanol (9/1). Example 14: {3-[4-(2,4-Diamino-pyrimidin-5-^ indol-2-yl}-pyrrolidin-1-yl-methanone (34mg, 18%) was obtained by reacting 5-(2- chloromethyl-6J-dimethoxy-benzofuran^-ylmethyl)-pyrimidine-2,4-diamine (136mg, 0.355mmol) with zinc chloride (48mg, 0.355mmol) and the salt of (1H-indol-2-yl)- pyrrolidin-1-yl-methanone obtained by reactiong a 3M-solution of ethyl magnesium bromide in diethyl ether (0.710mL, 2.13mmol) and (1H-indol-2-yl)-pyrrolidin-1-yl- methanone (457mg, 2.13mmol). MS ESI m/z: 527.1 [M+H]+. Example 15: 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyI)-6)7-dimethoxy-benzofuran-2-ylmethyl]-5-methoxy-1H-indole-2-carboxylic acid dimethylamide (18mg, 11%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2]4« diamine (113mg, 0.295mmol) with zinc chloride (40mg, 0.295mmol) and the salt of 5-methoxy-1H-indole-2-carboxyIic acid dimethylamide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (0.590mL, 1.7 mmol), and 5-methoxy-1H-indole-2-carboxylic acid dimethylamide (386mg, 1.77mmol). MS ESI m/z: 531.1 [M+Hf. Example 16: 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide (18mg, 6%) was obtained by reacting 5-(2-chloromethyl-6J7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine (198mg, 0.513mmol) with zinc chloride (70mg, 0.513mmol) and the salt of 1H-indole-2-carboxylic acid methoxy-methyl-amide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (1.03mL, 3.08mmol)( and 1H-indole-2-carboxylic acid methoxy-methyl-amide (629mg, 3.08mmol). MS ESI M/Z:: 517.2 [M+H]+; Structure confirmed by 1H NMR 400 MHz in DMSO-d6. Example 17: 5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide (9mg, 3%) was obtained by reacting 5-(2-chloromethyl-617-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine (183mg, 0.476mmol) with zinc chloride (65mg, 0.476mmol) and the salt of 5-chloro-1H-indole-2-carboxylic acid dimethylamide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (0.95mL, 2.86mmol), and 5-chloro-1H- indole-2-carboxylic acid dimethylamide (636mg, 2.86mmoi). MS ESI m/z: 535.2 [M+Hf; Structure confirmed by 1H NMR 400 MHz in DMSO-d6. Example 18: 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6)7-dimethoxy-ben2ofuran"2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic, acid dimethylamide (22mg, 25%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)»pyrimidine"214" diamine (190mg, 0.494mmol) with zinc chloride (67mg, 0.494mmol) and the salt of 5-fluoro-1H-indole-2-carboxylic acid dimethylamide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (0.98mL, 2.96mmol), and 5-fluoro-1H-indole-2-carboxylic acid dimethylamide (613mg, 2.96mmol). MS ESI M/Z:: 519.3 [M+H]+; Structure confirmed by 1H NMR 400 MHz in DMSO-d6. Example 19: S-^^^-Diamino-pyrimidin-S-ylmethyO-e.y-dimethoxy-benzofuran^-ylmethyll-IH-indole-2-carboxylic acid NX-dimethyl-hydrazide (13mg, 6%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran"4-ylmethyl)-pyrimidine-2,4-diamine (160mg, 0.416mmol) with zinc chloride (57mg, 0.416mmol) and the salt of 1H-indole-2-carboxylic acid N,N'-dimethyl-hydrazide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (0.83 mL, 2.49 mmol), and 1H-indole-2-carboxylic acid N,N'-dimethyl-hydrazide (507mg, 2.49mmol). MS ESI m/z: 516.2 [M+H]+. Example 20: 5-Chloro«3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-617-dimethoxy-benzofuran-2-ylmethyl]-1 H-indole-2-carboxylic acid methoxy-methyl-amide (8mg, 2.5%) was obtained by reacting 5-(2-chloromethyI-6)7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine (216mg, 0.560mmol) with zinc chloride (76mgt 0.560 mmol) and a the salt of 5-chloro-1 H-indole-2-carboxylic acid methoxy-methyl-amide obtained by reacting a 3M-solution of ethyl magnesium bromide in diethyl ether (1.08mL, 3.24mmol), and 5-chloro-1 H-indole-2-carboxylic acid methoxy-methyl-amide (771 mg, 3.24mmol). MS ESI m/z: 552.1 [M+H]+. Example 21: See Scheme 3 To a solution of ^-(Z^-Diamino-pyrimidin-S-ylmethyO-ej-dimethoxy-benzofuran^-yl]-methanol (1 eq, 2.74g, 8.3mmol) in chloroform, manganese oxide (10 eq, 7.22g, 83mmoI) was added at room temperature under argon. The reaction mixture was heated at 45°C. After completion of the reaction, the hot mixture is filtered and the manganese oxide residue is washed with hot acetonitrile. The filtrate is evaporated to give 4«(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran«2-carbaldehyde as a yellow solid (1.63g, 60%). To a suspension of 4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7Kiimethoxy-benzofuran-2-carbaldehyde (1 eq, 190mg, 0.58mmol) and 5-fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide (2 eq, 886mg, 1.74mmol) in Acetic acid (C=0.20 M), a 30% solution of HBr in acetic acid (10 eq, 1.2mL) was added slowly at 5 °C under argon. The purple mixture was stirred 20 minutes under Argon until completion. The resulting mixture was poured onto ice water, basified to pH 8 by adding a saturated solution of NaHC03. After centrifugation of the resulting suspension was filtered and the resulting precipitate was lyophilized overnight. The residue was then digested in methanol to precipitate the amide in excess. After filtration, the filtrate was evaporated to give the compound of formula XII. This compound was used for the next step without further purification. To a solution of the dimere adduct XII (1 eq) in trifluoroacetic acid, boron trifluoride-ethyletherate (3 eq) and triethylsilane (3 eq) were added at 0°C under argon. The reaction mixture was then heated at 30°C until completion. The resulting mixture was poured onto ice, potassium carbonate was added until pH 8. Sodium acetate was added to saturate the medium and the product was extracted with acetonitrile. The organic layer was evaporated and the residue lyophilized overnight. The precipitate obtained was digested in methanol and the resulting filtrate was evaporated. 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide (8.6mg, 2.7% over the two steps) was obtained after purification by FC, gradient from CH2CI2 to CH2CI2/methanol (93/7). MS ESI m/z\ 535.5 [M+H]+ General Procedure E: Measurement of antimicrobial activity Antimicrobial susceptibility testing was performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) procedure [M7-A5, 2001]. M7-A5 (2001) : Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard —Fifth Edition American National Standard. The minimal inhibition concentration (MIC) of the compounds regarding resistant strains is in the range of 0.25-2.0 ^ig/mL depending on the strain used. General Procedure F: Purified Enzymes and DHFR Enzyme Assay: Bacterial and human dihydrofolate reductases were purified, shown to be functional and used in DHFR assays as described by Baccanari & Joyner (Baccanari, D.P. and Joyner, S.S. 1981. Dihdrofolate reductase hysteresis and its effect on inhibitor binding analyses. Biochem. 20, 1710-1716) The IC50 of the compounds regarding DHFR mutants is in the range of 0.5-8.0 jiM. Claims 1. Compounds of the general formula I wherein R1 represents the groups whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group wherein R8 represents, lower alkyloxy, lower alkylamino, or lower alkyl with 1 to 4 carbon atoms; R9 represents, lower alkyl with 1 to 4 carbon atoms; R8 and R9 together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen. R6 represent hydrogen, halogen, nitro, or lower alkyloxy; R7 represents hydrogen; R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring; R4 represents hydrogen; and pharmaceutical^ acceptable salts thereof. 2. Compounds of the general formula I' Formula P wherein R1 represents the groups whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group wherein R8 represents, lower alkyloxy, or lower alkyl with 1 to 4 carbon atoms; R9 represents, lower alkyl with 1 to 4 carbon atoms; R8 and R9 together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen. R6 represent hydrogen, halogen, nitro, or lower alkyloxy; R7 represents hydrogen; R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring; R4 represents hydrogen; and pharmaceutical^ acceptable salts thereof. 3. Compounds of the general formula II wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I; R7 represents hydrogen; and pharmaceutical^ acceptable salts thereof. 4. Compounds of the general formula III wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I; R7 represents hydrogen; and pharmaceutical^ acceptable salts thereof. 5. Compounds of the general formula IV wherein R2 and R3 represent methyl; R4 represents hydrogen; R5 and R6 are as defined in formula I; R7 represents hydrogen; and pharmaceutical^ acceptable salts thereof. 6. Compounds selected from the group consisting of: 5«[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; 5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)«benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; S-p^lH-lndol-S-ylmethylJ-ej-dimethoxy-benzofuran^ylmethyn-pyrimidine^^- diamine; 5-[6I7-Dimethoxy-2-(2-methyl-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]- pyrimidine-2,4-diamine; S-^e-Fluoro-IH-indol-S-ylmethyO-ej-dimethoxy-benzofuran^-ylmethylj-pyrimidine- 2,4-diamine; {3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6?7-dimethoxy-benzofuran-2-ylmethyl]-1H- indol-2-yl}-morpholin-4-yl-methanone; 3-[4«(2,4-DiaminO"pyrimidin-5-ylmethyl)-6l7«dimethoxy-benzofuran-2-ylmethyl]-1H- indole-2-earboxylic acid dimethylamide; 5-[6,7-Dimethoxy-2-(5-nitro-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine- 2,4-diamine; {3-[4-(2,4«Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H- indol-2-yl}-pyrrolidin-1-yl-methanone; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6)7-dimethoxy«benzofuran-2-ylmethyl]-5- methoxy-1H-indole-2-carboxylic acid dimethylamide; 3-[4-(2,4-Diamino«pyrimidin-5-ylmethyl)-6,7-dimethoxy«benzofuran-2-ylmethyl]-1H- indole-2-carboxylic acid methoxy-methyl-amide; 5-Chloro-3-[4-(214-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-1H-indole-2-carboxylic acid dimethylamide; 3-[4-(2t4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy«benzofuran-2-ylmethyl]-5- fluoro-1H-indole-2-carboxylic acid dimethylamide; 5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-1H-indo!e-2-carboxylic acid methoxy-methyl-amide; 3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H- indole-2-carboxylic acid N,N'-dimethyl-hydrazide; S-^^^-Diamino-pyrimidin-S-ylmethyO-ej-dimethoxy-benzofuran^-ylmethyll-S- fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide; and pharmaceutical^ acceptable salts thereof. 7. Intermediates of the general formula XI and XII. XI XII wherein R2, R3, R4, R5 and R6 have the meaning given in fomula I in claim 1 and 2. 8. Pharmaceutical compositions comprising one or more compounds of any one of claims 1 to 6 and usual inert carrier materials. 9. Pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens comprising one or more compounds of any one of claims 1 to 6 and usual inert carrier materials. 10. The compounds of any one of claims 1 to 6 for use as medicaments. 11. The compounds of any one of claims 1 to 6 for use as medicaments for the treatment of infection. 12. The compounds of any one of claims 1 to 6 for use as medicaments for the treatment of infection caused by Gram positve or Gram negative pathogens or by a mixture thereof. 13. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions. 14. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions for the treatment of infections. 15. The use of one or more compounds of any one of claims 1 to 6 as active ingredients for the production of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof. 16. A process for the manufacture of pharmaceutical compositions containing one or more compounds as claimed in any one of claims 1 to 6 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutical^ acceptable inert carrier materials and adjuvants in a manner known per se. 17. A process for the manufacture of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof containing one or more compounds as claimed in any one of claims 1 to 6 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutical^ acceptable inert carrier materials and adjuvants in a manner known per se.

Documents:

0081-chenp-2006 abstract-granded.pdf

0081-chenp-2006 claims-granded.pdf

0081-chenp-2006 description (complete)-granded.pdf

0081-chenp-2006-abstract.pdf

0081-chenp-2006-claims.pdf

0081-chenp-2006-correspondnece-others.pdf

0081-chenp-2006-correspondnece-po.pdf

0081-chenp-2006-description(complete).pdf

0081-chenp-2006-form 1.pdf

0081-chenp-2006-form 18.pdf

0081-chenp-2006-form 3.pdf

0081-chenp-2006-form 5.pdf

0081-chenp-2006-pct.pdf